EF
TVTX icon

Empowered Funds’s Travere Therapeutics TVTX Stock Holding History

Empowered Funds’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98M Buy
87,608
+2,788
+3% +$124K 0.03% 711
2026
Q1 		$2.52M Buy
+84,820
New +$2.54M 0.02% 976

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Empowered Funds's TVTX Position: Q2 2026 in Review

Empowered Funds increased its Travere Therapeutics (TVTX) stake by 3.3% in Q2 2026, buying an estimated $124K and bringing the position to 87,608 shares worth $4.98M. The position accounts for 0.03% of the portfolio, ranked #711.

Empowered Funds first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Empowered Funds held 87,608 shares of Travere Therapeutics worth $4.98M as of Q2 2026.
  • Empowered Funds bought 2,788 Travere Therapeutics shares in Q2 2026, an estimated $124K.
  • Travere Therapeutics made up 0.03% of Empowered Funds's portfolio in Q2 2026, its #711 holding.
  • Empowered Funds first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.